目的 比较西格列汀与瑞格列奈治疗初诊2型糖尿病（T2DM）的临床疗效。方法 回顾性分析104例初诊T2DM患者的临床资料，其中54例为西格列汀治疗（G组），50例为瑞格列奈治疗（R组）。比较两组治疗前后空腹血糖（FPG）、餐后2 h血糖（2 hPG）、糖化血红蛋白（HbA1c）、总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）水平及糖化血红蛋白（HbA1c）达标率、体质指数（BMI）变化量和低血糖发生率。结果 两组治疗后的FPG、2hPG、HbA1c水平均明显低于治疗前，同组治疗前后比较差异有统计学意义（P<0.05），但组间差异无统计学意义。两组治疗前后的TG、TC、HDL-C水平均无明显变化。两组HbA1c达标率无统计学意义，G组BMI变化量及低血糖发生率明显低于R组，组间差异有统计学意义（P<0.05）。结论 西格列汀与瑞格列奈治疗初诊T2DM患者均能有效降低血糖，对血脂无明显影响，但西格列汀在控制BMI和减少低血糖方面更有优势。

Objective Tocompare the clinical efficacy of Glipizide and Repaglinide in the treatment of newly diagnosed type 2 diabetes (T2DM). Methods The clinical data of 104 patients with newly diagnosed T2DM were retrospectively analyzed, among them, 54 cases were treated with Glipizide (group G), and 50 cases were treated with Repaglinide (group R). The levels of FPG, 2hPG, HbA1c, TC, TG and HDL-C before and after treatment and HbA1c compliance rates, BMI variation and incidences of hypoglycemia between two groups were compared. Results The levels of FPG, 2hPG and HbA1c after treatment in the two groups were significantly lower than those before treatment (P < 0.05), and there were no significant difference between the groups. There were no significant changes in TG, TC and HDL-C levels before and after treatment in the two groups. There were no significant changes in HbA1c compliance rates between the two groups, and the BMI variation and incidences of hypoglycemia in the group G were significantly lower than those in the group R (P < 0.05). Conclusion BothGlipizide and Repaglinide in the treatment of T2DM can reduce blood glucose effectively, and no significant effect on blood lipids,But Glipizide has more advantages in controlling BMI and reducing hypoglycemia.